Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 444 across all filing types
Latest filing 2025-01-07 Regulatory Filings
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Group of companies' accounts made up to 2024-06-30
Regulatory Filings
2025-01-07 English
Grant & Cancellation of Options
Director's Dealing Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Renalytix plc, dated December 30, 2024. The content explicitly details the 'Grant & Cancellation of Options / PDMR Dealings' for Persons Discharging Managerial Responsibilities (PDMRs). This type of filing, which reports personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it involves options (which could sometimes relate to CAP or SHA), the primary purpose and structure of the filing are to disclose insider transactions as required by market regulations, making DIRS the most accurate classification. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it an earnings release (ER) or annual report (10-K).
2024-12-30 English
Director/PDMR share purchase
Director's Dealing Classification · 99% confidence The document is a formal announcement released via RNS (London Stock Exchange news service) dated December 20, 2024. The content explicitly details a 'Director/PDMR share purchase' where the Chief Technology Officer, Fergus Fleming, bought 25,000 ordinary shares. This type of filing, reporting personal share transactions by company directors and executives (insider trades), directly corresponds to the definition of 'Director's Dealing'. The presence of the RNS header and the specific nature of the transaction confirm this classification over general regulatory filings (RNS) or other corporate actions.
2024-12-20 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is announcing the 'Result of AGM' and provides a detailed table showing the voting results for various resolutions (e.g., 'Receive and adopt the UK 2024 Annual Report', 'Approve Directors' Remuneration Report'). This content directly corresponds to the official results from a shareholder meeting. The RNS Number format and the mention of 'RNS' confirm it is a regulatory announcement, but the specific content points overwhelmingly to the Declaration of Voting Results & Voting Rights Announcements category.
2024-12-19 English
AGM Statement
AGM Information Classification · 99% confidence The document is explicitly titled "AGM Statement" and begins by stating it is providing an update to shareholders ahead of the Annual General Meeting ("AGM"). It contains a detailed statement from the Executive Chairman covering recent funding, commercial strategy, and financial outlook, which is typical content presented at an AGM. The RNS Number format (6674Q) suggests a regulatory announcement, but the content is clearly focused on the AGM proceedings/update. This aligns perfectly with the definition for AGM Information (AGM-R). It is not a full 10-K, a short ER, or a simple announcement of a report (RPA/RNS).
2024-12-19 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 4618Q' by Renalytix PLC on '17 December 2024'. This form is used to report changes in significant share ownership (crossing thresholds) by entities like UBS Group AG. This directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content is a mandatory regulatory disclosure regarding ownership changes, making MRQ the most precise classification.
2024-12-17 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.